PhaseBio Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
60
- Investments
-
2
- Share Price
-
$0.07
- (As of Wednesday Closing)
PhaseBio Pharmaceuticals General Information
Description
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The key product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Contact Information
Website
www.phasebio.comCorporate Office
- One Great Valley Parkway
- Suite 30
- Malvern, PA 19355
- United States
Corporate Office
- One Great Valley Parkway
- Suite 30
- Malvern, PA 19355
- United States
PhaseBio Pharmaceuticals Stock Performance
As of 02-Nov-2022, PhaseBio Pharmaceuticals’s stock price is $0.07. Its current market cap is $3.5M with 49.9M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.07 | $0.09 | $0.07 - $3.02 | $3.5M | 49.9M | -$2.13 |
PhaseBio Pharmaceuticals Financials Summary
As of 30-Jun-2022, PhaseBio Pharmaceuticals has a trailing 12-month revenue of $818K.
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 18,125 | 80,053 | ||
| Revenue | 818 | 10,831 | 0 | 575 |
| EBITDA | (100,255) | (126,745) | (96,849) | (39,553) |
| Net Income | (102,840) | (131,071) | (98,565) | (39,247) |
| Total Assets | 22,166 | 60,540 | 50,357 | 82,494 |
| Total Debt | 5,372 | 8,320 | 14,066 | 16,477 |
PhaseBio Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PhaseBio Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
PhaseBio Pharmaceuticals Comparisons
Industry
Financing
Details
PhaseBio Pharmaceuticals Competitors (105)
One of PhaseBio Pharmaceuticals’s 105 competitors is Altimmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
PhaseBio Pharmaceuticals Patents
PhaseBio Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022240754-A2 | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody | Inactive | 10-May-2021 | ||
| WO-2022240754-A3 | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody | Inactive | 10-May-2021 | ||
| US-20230173030-A1 | Vasoactive intestinal peptide fusion proteins for the treatment of covid-19 | Inactive | 05-May-2020 | ||
| WO-2021226244-A1 | Vasoactive intestinal peptide fusion proteins for the treatment of covid-19 | Inactive | 05-May-2020 | ||
| WO-2021030196-A1 | Elp fusion proteins comprising parathyroid hormone for controlled and sustained release | Inactive | 09-Aug-2019 | C07K14/635 |
PhaseBio Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PhaseBio Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PhaseBio Pharmaceuticals Investments (2)
PhaseBio Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Viamet Pharmaceuticals (Intellectual properties) for . The deal was made on 13-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Viamet Pharmaceuticals (Intellectual properties) | 13-Jan-2020 | Corporate Asset Purchase | Buildings and Property | ||
| ImmunoForge | 01-Mar-2019 | Early Stage VC | Drug Discovery |
PhaseBio Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
PhaseBio Pharmaceuticals FAQs
-
When was PhaseBio Pharmaceuticals founded?
PhaseBio Pharmaceuticals was founded in 2002.
-
Where is PhaseBio Pharmaceuticals headquartered?
PhaseBio Pharmaceuticals is headquartered in Malvern, PA.
-
What is the size of PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals has 60 total employees.
-
What industry is PhaseBio Pharmaceuticals in?
PhaseBio Pharmaceuticals’s primary industry is Drug Delivery.
-
Is PhaseBio Pharmaceuticals a private or public company?
PhaseBio Pharmaceuticals is a Public company.
-
What is the current stock price of PhaseBio Pharmaceuticals?
As of 02-Nov-2022 the stock price of PhaseBio Pharmaceuticals is $0.07.
-
What is the current market cap of PhaseBio Pharmaceuticals?
The current market capitalization of PhaseBio Pharmaceuticals is $3.5M.
-
What is PhaseBio Pharmaceuticals’s current revenue?
The trailing twelve month revenue for PhaseBio Pharmaceuticals is $818K.
-
Who are PhaseBio Pharmaceuticals’s competitors?
Altimmune, TScan Therapeutics, Regenxbio, Mesoblast, and Ayala Pharmaceuticals are some of the 105 competitors of PhaseBio Pharmaceuticals.
-
What is PhaseBio Pharmaceuticals’s annual earnings per share (EPS)?
PhaseBio Pharmaceuticals’s EPS for 12 months was -$2.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
